Key Points
- The Philippine FDA issued Advisory No. 2025-1487;
- Vape products with medicinal claims must secure Licenses to Operate;
- All manufacturers, importers, distributors and retailers are covered;
- Products must be registered as pharmaceutical products;
- Compliance is required to ensure safety and quality standards.
2Firsts, December 2025,22 – According to SunStar Philippines, the Philippine Food and Drug Administration (FDA) now requires all establishments selling Vaporized Nicotine and Non-Nicotine Products (VNNPs) and Novel Tobacco Products (NTPs) with medicinal or therapeutic claims to secure Licenses to Operate.
Based on Advisory No. 2025-1487, the FDA said that manufacturers, traders, importers, exporters, wholesalers and retailers offering such products must apply for licenses as pharmaceutical establishments under the Department of Health.
The FDA added that all VNNPs and NTPs with medicinal or therapeutic claims must be registered prior to manufacture, distribution and sale.
The agency said these products must be registered as pharmaceutical products through the Center for Drug Regulation and Research (CDRR).
The FDA urged all stakeholders to fully comply with the new requirements, stating that adherence to regulatory standards is necessary to ensure the safety, efficacy and quality of VNNPs and NTPs with medicinal or therapeutic claims in the market.
Image Source: SunStar Philippines
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
